Cargando…
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquire...
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501619/ https://www.ncbi.nlm.nih.gov/pubmed/36146829 http://dx.doi.org/10.3390/v14092023 |
| _version_ | 1784795519544983552 |
|---|---|
| author | Basile, Kerri Rockett, Rebecca J. McPhie, Kenneth Fennell, Michael Johnson-Mackinnon, Jessica Agius, Jessica E. Fong, Winkie Rahman, Hossinur Ko, Danny Donavan, Linda Hueston, Linda Lam, Connie Arnott, Alicia Chen, Sharon C.-A. Maddocks, Susan O’Sullivan, Matthew V. Dwyer, Dominic E. Sintchenko, Vitali Kok, Jen |
| author_facet | Basile, Kerri Rockett, Rebecca J. McPhie, Kenneth Fennell, Michael Johnson-Mackinnon, Jessica Agius, Jessica E. Fong, Winkie Rahman, Hossinur Ko, Danny Donavan, Linda Hueston, Linda Lam, Connie Arnott, Alicia Chen, Sharon C.-A. Maddocks, Susan O’Sullivan, Matthew V. Dwyer, Dominic E. Sintchenko, Vitali Kok, Jen |
| author_sort | Basile, Kerri |
| collection | PubMed |
| description | In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2. |
| format | Online Article Text |
| id | pubmed-9501619 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95016192022-09-24 Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine Basile, Kerri Rockett, Rebecca J. McPhie, Kenneth Fennell, Michael Johnson-Mackinnon, Jessica Agius, Jessica E. Fong, Winkie Rahman, Hossinur Ko, Danny Donavan, Linda Hueston, Linda Lam, Connie Arnott, Alicia Chen, Sharon C.-A. Maddocks, Susan O’Sullivan, Matthew V. Dwyer, Dominic E. Sintchenko, Vitali Kok, Jen Viruses Brief Report In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2. MDPI 2022-09-13 /pmc/articles/PMC9501619/ /pubmed/36146829 http://dx.doi.org/10.3390/v14092023 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Brief Report Basile, Kerri Rockett, Rebecca J. McPhie, Kenneth Fennell, Michael Johnson-Mackinnon, Jessica Agius, Jessica E. Fong, Winkie Rahman, Hossinur Ko, Danny Donavan, Linda Hueston, Linda Lam, Connie Arnott, Alicia Chen, Sharon C.-A. Maddocks, Susan O’Sullivan, Matthew V. Dwyer, Dominic E. Sintchenko, Vitali Kok, Jen Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine |
| title | Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine |
| title_full | Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine |
| title_fullStr | Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine |
| title_full_unstemmed | Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine |
| title_short | Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine |
| title_sort | improved neutralisation of the sars-cov-2 omicron variant following a booster dose of pfizer-biontech (bnt162b2) covid-19 vaccine |
| topic | Brief Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501619/ https://www.ncbi.nlm.nih.gov/pubmed/36146829 http://dx.doi.org/10.3390/v14092023 |
| work_keys_str_mv | AT basilekerri improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT rockettrebeccaj improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT mcphiekenneth improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT fennellmichael improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT johnsonmackinnonjessica improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT agiusjessicae improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT fongwinkie improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT rahmanhossinur improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT kodanny improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT donavanlinda improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT huestonlinda improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT lamconnie improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT arnottalicia improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT chensharonca improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT maddockssusan improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT osullivanmatthewv improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT dwyerdominice improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT sintchenkovitali improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine AT kokjen improvedneutralisationofthesarscov2omicronvariantfollowingaboosterdoseofpfizerbiontechbnt162b2covid19vaccine |